SPECIFIC APPROACHES TO PLANNING OF PATIENTS WITH PRIMARY AND SECONDARY BRAIN TUMORS USING THE TOMOTHERAPY PLANNING SYSTEM

S.P. Odarchenko, M.B. Gumieniuk*, K.V. Gumieniuk, O.V. Zinvaliuk, D.S. Sinchuk
LLC “Ukrainian Center of Tomotherapy”, Kropyvnytskyi, Ukraine

Abstract. Nowadays only several medical centers of Ukraine are equipped with special linear accelerators for treating patients using Image-Guided Radiation Therapy (IGRT) and Intensity-Modulated Radiotherapy (IMRT), apart from 3DCRT methods. Sequential (SEQ) and Simultaneous Integrated Boost (SIB) are common IMRT techniques for whole brain irradiation and metastasis treatment using TomoTherapy system TomoHD. The radiotherapy system, mentioned above, is innovation for oncological diseases treatment in Ukraine as well as in post Soviet Union countries in general. Thus, one of main goals of the work is to define the quality of different therapeutic plans, to identify and describe the main features of treatment plans preparation and creating and to describe some specific approaches for SIB and SEQ techniques in planning of patients with brain tumors using the TomoTherapy Planning System.

Key words: Brain cancer, conformity index, homogeneity index, IGRT, IMRT, sequential and simultaneous integrated boost, TomoTherapy Tomo HD

DOI: 10.21175/RadProc.2017.34

1. INTRODUCTION

The Intensity-Modulated Radiotherapy (IMRT) is the most suitable radiotherapy technique for brain treating in Ukrainian center of TomoTherapy. It is provided in two ways: Sequential (SEQ) and Simultaneous Integrated Boost (SIB). The purpose of this work is to define the quality of therapeutic plans in different cases, to identify and describe the main features of treatment plans creating and to describe some specific approaches for SIB and SEQ techniques in planning preparing of patients with brain tumors using the TomoTherapy Planning System.

For the SIB technique, the different dose is delivered to PTV-LR and PTV-HR simultaneously in one fraction, during the same procedure. The number of fractions of SIB is less than SEQ.

For SEQ technique, the planning target volume-low risk (PTV-LR) is irradiated in the first plan and after the end of first course; the dose is boosted to the planning target volume-high risk (PTV-HR) with the second plan in the second course. Both plans have the same dose per fraction during the whole treatment.

The patients are treated with the radiotherapy system TomoTherapy Tomo HD.

2. MATERIALS AND METHODS

2.1. Contouring

25 therapeutic plans, which were used for treating patients with brain tumors, were analyzed. They were created in the time range from June 2015 till the end of 2016. All patients were treated by using the radiotherapy system TomoTherapy Tomo HD.

The contours of the target (GTV, CTV, PTV (CTV + 0.3 cm)), and critical organs (eyes, lenses, optical nerves, chiasm, the brain and brainstem) were determined by radiation therapists with using MiM Maestro contouring software. The PTV1 for SIB included GTV for metastases which were defined as the contrast-enhancing lesion on T1-weighted MRI plus 3 mm uniform margin. The PTV2 for WBRT included the whole brain plus 3 mm margin excluding PTV1. After the end of therapists contouring, medical physicists created different additional "logical" structures. The structures are unique for different plans and techniques and are used for a better control of dose distribution in the target and around it, especially in the critical volumes and areas.

2.2. Dividing structures

If the organ at risk (OAR) has common parts with the target (overlapped structures), it is important to avoid the dose getting maximums in the common areas.

*gymenick@gmail.com
of the target and OAR. For that reason, OAR is divided into substructures (Fig. 1):

PTV OAR is the part of OAR volume, which is fully located in the PTV. In this volume it is very important to control the maximum dose.

OAR plan (OAR-) is part of OAR, which is located out of the PTV volume.

In this volume a high dose gradient for maximum protection of the part of OAR must be reached.

The part of PTV, which does not contain any common volume with OARs, is called as PTV plan.

So we get the situation, where PTV consists of smaller parts with a different dose coverage priority, such as PTV OAR (one or more) and OAR plan.

The real dose distribution is controlled and evaluated by using Dose Volume Histogram (DVH) curves, which corresponds to the real OARs and PTVs.

2.3. Dmin structures

Dmin1 is an additional circular (spherical) structure, created around a target.

Dmin2 is the second additional circular (spherical) structure created around Dmin1 (Fig. 2).

Their main goals are:
- to ensure good conformity and steep gradient of high doses around the target;
- to give additional control over the maximum dose beyond the target volume;
- to ensure uniformity and decline dose in regions of medium and low doses outside the target volume.

Dmin1 is 5mm outer ring and Dmin2 is second ring with size of 20-25 mm are shown.

2.4. Simultaneous integrated boost (SIB) structures

If it is necessary to irradiate overlapped targets with different doses, one or two ring structures RingX are made, which provide a uniform transition of the dose from PTV HR to PTV LR (Fig. 3). Also, for non-overlapping volumes, a special logical volume PTVLR_nR (orange region in Figure 3) is created by extracting previously made rings from PTV LR for a more clear DVH and statistical analysis.

2.5. Plan calculation

After creating all additional structures, CT and RT structures files are sent to the planning station. All dosimetric calculations were made by using TomoTherapy planning system. All structures are divided into two groups: targets and OARs. Each group has its own hierarchy.

Besides, additional parameters must be selected before starting the planning procedure (Modulation factor (MF), Field width (FW), Mode (IMRT or 3D), IVDT curve, red lasers position).

The optimization of the plan is started after calculating the dose beamlets and inserting the necessary parameters and values.

2.6. Automatic workflows

Preparation for plan calculating and plan optimizing are very time consuming processes.

Standard TomoTherapy software has poor functionality and there is no possibility of CT and MRI images fusion for example. Also there is no possibility of different “logical” structures creation (no “Boolean
operations” available). So for delineation of different structures third party contouring software is needed. At UCT department MIM maestro software is used. It is a commercial software solution for radiation oncology.

Reducing of beamlet calculation time is very important, but the only solution of the problem is upgrading of the system to the VoLO (Voxel-Less Optimization) Technology. To make workflow faster we decided to reduce the additional structures creating time. Automatic workflow presets were made in MIM software for main treatment sites. After finishing of targets and OARs delineation by the physician (default list of “empty” structures with default names must be chosen before starting of delineation), medical physicist makes revision of all structures contours and, in most cases, launches automatic workflow preset realization. All additional contours are generated automatically (Fig. 4). This task usually takes 2-5 minutes. In case of manual creation of all logical structures, half an hour or sometimes even more time was needed.

After the end of contours creation CT images and RT structures files are sent to Tomoserver.

In TomoTherapy planning software presets for different sites were also created (Fig. 5). The chosen preset fills automatically all necessary data of plan properties (FW, pitch, modulation factor, etc.) and structures initial priority, importance and dose restrictions (Fig. 6). Beamlet calculation may be started immediately in background mode. Structure properties importance and restrictions may be changed during the optimization, but very often the protocols initial values (experience based values are set) are good enough for getting fine planning results (Fig. 7).

2.7. Preliminary assessment plan

The aim is to obtain such a dose distribution in which 95% of the prescribed dose covers 99% of the target. At least, 95% of the PTV volume must be covered by 95% of the prescribed dose, if OAR is partially or fully included in PTV, and there is no possibility to irradiate it with the full prescribed dose [5]. Each individual case is always discussed with a therapist.
The maximum dose in point should not exceed 107% of the prescribed dose or, in some complicated cases, D1% should not exceed 107% of the prescribed dose (Fig. 8).

For dose distribution uniformity analyzing, the dose homogeneity index (HI) is used, which is calculated according to (1).

\[ HI = \frac{D1\% - D99\%}{D50\%} \]  

where D1% is dose of 1% volume of the PTV (maximum dose), D99% is dose of 99% volume the PTV (minimum dose), D50% is median dose [1].

A value of 0 corresponds to absolute dose homogeneity within the PTV.

2.9. Analysis of dose conformity

Paddick CI is a conformity index that shows how well the target is covered by the dose (95% of the prescribed dose) and assesses how close the 95% isodoseline is to the target [2].

CI value can vary between 0 and 1, the value of i is the most accurate target coverage without the reference dose exposure of healthy surrounding tissues, a value of 0 indicates a lack of conformity which may arise in the case of "miss" or when it is a large amount of irradiated healthy tissue [3].

\[ CI = \left( \frac{TV}{DVRx} \right) \left( \frac{TV}{DVRx} \right) \]  

where TV is volume of the target,
TVRdx volume of target receiving 95% or higher percent of the prescribed dose
VDRx is total volume, receiving 95% or higher percent of the prescribed dose.

2.10. Plan verification

Plans verification was performed with the software PTW VeriSoft and Octavius phantom with detector 2D-array 729 (PTW). Test results were within 97% - 100% (analysis of the following parameters: Gamma 3D, 3mm distance to agreement /3% dose difference with ref. to the local dose).

3. Results

Prescribed doses were:

- DPTV46=46 and DPTV60=60 Gy (2 Gy/fr) for SEQ IMRT technique per 23 and 30 fractions respectively.
- DPTV LR=30 and DPTV HR=40 Gy (3 - 4 Gy/fr) for SIB IMRT technique per 10 fractions.

Medical plans features: field width was 1.0 - 2.5 cm; pitch was 0.287; initial modulation factor was 3.4; real modulation factor range varied from 2.1 to 2.7. Optimization options were set in the next way: the value of the average dose that covered VPTV 100% met the prescribed dose, the dose (DPTV 99%), which covered the VPTV 99% was greater than 95% of the prescribed dose, in severe cases the dose that covered VPTV 95% was greater than 95% of the prescribed dose. Maximum dose in point was Dmax ≤ 107% of the prescribed dose.

The minimum dose at point Dmin was > 90% of the prescribed dose.

The resulting 17 SEQ plans were characterized by the high uniformity of dose distribution DPTV95% = 97-100%, Dmax was 102 - 105%, Dmean was 100%, the average HImean was 0.048, HImax was 0.123, HImin was 0.0175, the average value CImean was 0.86, CImax was 0.994, CImin was 0.673. The average exposure time was 328 s. (From 252 s to 432 s) (Table 1).

For 8 SIB plans the results are shown in Table 2. The resulting 8 SIB plans were characterized by the high uniformity and conformity of dose distribution:

- for PTV HR:
  HImean was 0.066; HImax was 0.113; HImin was 0.051.
  CImean was 0.755; CImax was 0.753; CImin was 0.734.
- for PTV LR
  HImean was 0.074; HImax was 0.081; HImin was 0.063.
  CImean was 0.838; CImax was 0.852; CImin was 0.754.

The average exposure time Tav was 411 s. (From 384 s to 450 s).

<table>
<thead>
<tr>
<th>Table 1. Cl, HI and time of SEQ plans</th>
<th>T min</th>
<th>HI</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>0.058</td>
<td>0.863</td>
<td></td>
</tr>
<tr>
<td>4.4</td>
<td>0.124</td>
<td>0.905</td>
<td></td>
</tr>
<tr>
<td>7.2</td>
<td>0.059</td>
<td>0.884</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>0.072</td>
<td>0.860</td>
<td></td>
</tr>
<tr>
<td>5.7</td>
<td>0.035</td>
<td>0.880</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>0.033</td>
<td>0.870</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>0.039</td>
<td>0.887</td>
<td></td>
</tr>
<tr>
<td>5.6</td>
<td>0.057</td>
<td>0.901</td>
<td></td>
</tr>
<tr>
<td>5.5</td>
<td>0.022</td>
<td>0.672</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>0.017</td>
<td>0.746</td>
<td></td>
</tr>
<tr>
<td>6.8</td>
<td>0.032</td>
<td>0.857</td>
<td></td>
</tr>
<tr>
<td>5.0</td>
<td>0.037</td>
<td>0.857</td>
<td></td>
</tr>
<tr>
<td>5.2</td>
<td>0.038</td>
<td>0.896</td>
<td></td>
</tr>
<tr>
<td>4.8</td>
<td>0.047</td>
<td>0.994</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>0.053</td>
<td>0.880</td>
<td></td>
</tr>
<tr>
<td>4.2</td>
<td>0.026</td>
<td>0.722</td>
<td></td>
</tr>
<tr>
<td>5.7</td>
<td>0.064</td>
<td>0.892</td>
<td></td>
</tr>
</tbody>
</table>
For both SEQ and SIB techniques, the organs at risk have received a dose that did not exceed the tolerance doses according to the QUANTEC [4], except for SEQ plans critical organs may have common parts with PTV46 and PTV60. Depending on that fact, different statistics were received for the same AORs (Table 3).

For SEQ plans critical organs dose is shown in Table 4.

<table>
<thead>
<tr>
<th>OARs</th>
<th>Not included in any PTV</th>
<th>Particularly or fully included only in PTV46</th>
<th>Particularly or fully included in PTV46 and PTV60</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean value of Dmax, Gy</td>
<td>Mean value of Dmax, Gy</td>
<td>Mean value of Dmax, Gy</td>
</tr>
<tr>
<td>Optic nerve L</td>
<td>(19.38-39.84)</td>
<td>(51.11-25.46)</td>
<td>(54.09-53.73)</td>
</tr>
<tr>
<td>Optic nerve R</td>
<td>(19.08-19.52)</td>
<td>(48.93-51.77)</td>
<td>(54.26-54.59)</td>
</tr>
<tr>
<td>Chiasm</td>
<td>(13.93-31.93)</td>
<td>(49.60-51.40)</td>
<td>(54.40-55.04)</td>
</tr>
<tr>
<td>Brain stem</td>
<td>(12.93-20.19)</td>
<td>(52.66-56.35)</td>
<td>(58.33-59.19)</td>
</tr>
<tr>
<td>Lens L</td>
<td>(10.80-9.80)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lens R</td>
<td>(5.10-9.80)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Eye L</td>
<td>(6.74-13.05)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Eye R</td>
<td>(10.80-21.20)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

For SIB plans critical organs dose is shown in Table 4.
PMid: 27536639
PMCnt: PMC5124807